期刊文献+

E1B缺陷腺病毒dl1520预感染CNE-2细胞对其致瘤性的影响 被引量:1

The effect of E1B-deleted Adenovirus dl1520 on the Tumorigenicity of preinfected Nasopharyngeal Carcinoma cell CNE-2
下载PDF
导出
摘要 目的探讨E1B-55KDa缺陷腺病毒dl1520预感染鼻咽癌细胞CNE-2对其致瘤性的影响。方法10MOI(感染复数)的dl1520感染CNE-2细胞后,按5%、20%的比例将感染细胞和未感染细胞混合后做裸鼠皮下注射,观察肿瘤生长情况并采用免疫组化检测腺病毒六邻体抗原,分析dl1520在肿瘤内的复制及分布情况。结果5%、20%组均可见肿瘤生长明显抑制,抑瘤率分别为30.59%、76.60%,P<0.01。免疫组化证实瘤内有大量病毒复制且20%组比5%组分布更广泛。结论dl1520预感染CNE-2细胞后对其裸鼠移植瘤的生长有明显抑制作用,进一步证实dl1520具有一定的抗肿瘤作用且病毒在瘤内的分布情况可影响抗肿瘤的效果。 Objective To evaluate the tumorigenicity of nasopharyngeal carcinoma cell CNE-2 preinfected with E1B-deleted adenovirus dl1520. Methods CNE-2 were infected with dl1520 at a 10 multiplicity of infection(MOI) for 3 hours and mixed with uninfected cell suspension at 5% and 20% rations;then cells were injected into the flanks of nude mice. The tumor growth was monitored and adenovirus hexon protein was detected by immunohistochemistry to evaluate propagation and distribution of dl1520 in tumor. Results In 5% and 20% groups tumor growth inhibition was observed obviously; inhibition rate was 30.59%、76.60%(P<0.01), respectively. Immunohistochemistry showed that distribution of dl1520 was more widely in 20% group than in 5% group. Conclusion Dl1520 can significantly inhibit the tumorigenicity of preinfected tumor cell; this further confirmed that dl1520 has anti-tumor effect which can be influenced by its distribution in tumor.
出处 《郧阳医学院学报》 2005年第2期72-73,76,F003,共4页 Journal of Yunyang Medical College
基金 国家杰出青年基金(编号39825124)
关键词 E1B缺陷腺病毒 预感染 鼻咽癌细胞 致瘤性 E1B-deleted adenovirus preinfection nasopharyngeal carcinoma cell tumorigenicity
  • 相关文献

参考文献6

  • 1Pennisi E. Training viruses to attack cancers[J]. Science, 1998,282(5392):1 244-1 246.
  • 2彭吉林,罗慧玲,刘然义,曾益新.E1B缺陷腺病毒dl1520联合化疗药物DDP体外对鼻咽癌细胞杀伤及诱导凋亡作用[J].郧阳医学院学报,2004,23(6):321-323. 被引量:2
  • 3Nemunaitis J, Ganly I, Khuri F, et al . Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55KD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase Ⅱ trial[J]. Cancer Research, 2000,60(20):6 359-6 366.
  • 4Mulvihill S, Warren R, Venook A, et al . Safety and feasibility of injection with an E1B-55Kda gene-deleted, replication-selective adenovirus(ONYX-015) into primary carcinomas of the pancreas: a phaseⅠtrial[J]. Gene Therapy, 2001,8(4):308-315.
  • 5Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration[J]. Clinical Cancer Research, 2000,6(12):4 908-4 914.
  • 6Heise CC, Williams A, Olesch J, et al . Efficacy of a replication-competent adenovirus(ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects[J]. Cancer Gene Therapy, 1999,6(6):499-504.

二级参考文献9

  • 1[1]Pennisi E. Training viruses to attack cancers[J]. Science, 1998,282(5392):1 244-1 246.
  • 2[2]Barker DD,Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection[J]. Virology, 1987,156(1):107-121.
  • 3[3]Sanchez-Prieto R, Quintanilla M, Cano A, et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene[J]. Oncogene, 1996,13(5):1 083-1 092.
  • 4[4]Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein[J]. Nature,1992,357(6373):82-83.
  • 5[5]Kao CC, Yew PR, Berk AJ. Domains required for in vitro association between the cellular p53 and the Ad2 E1B55K proteins[J]. Virology, 1990,179(2):806-814.
  • 6[6]Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J]. Science, 1996,274(5286):373-376.
  • 7[7]Boulanger PA, Blair GE. Express and interactions of human adenovirus oncoproteins[J]. Biochem J, 1991,275(2):281-299.
  • 8[8]Vousden KH. Regulation of the cell cycle by oncoproteins[J]. Semin Cancer Biol, 1995,6(2):109-116.
  • 9[9]Martin ME, Berk AJ. Adenovirus E1B55K represses p53 activation in vitro[J]. J Virol, 1998,72(4):3 146-3 154.

共引文献1

同被引文献5

  • 1彭吉林,罗慧玲,刘然义,曾益新.E1B缺陷腺病毒dl1520联合化疗药物DDP体外对鼻咽癌细胞杀伤及诱导凋亡作用[J].郧阳医学院学报,2004,23(6):321-323. 被引量:2
  • 2Pennisi E.Training viruses to attack cancers[J]. Science, 1998,282(5392):1 244-1 246.
  • 3McCormick F. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015[J]. Semin Cancer Biol,2000,10(6):453-459.
  • 4Ries SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520(ONYX-015)[J]. Nat Med,2000,6(10):1128-1133.
  • 5Matsubara S,Wada Y,Gardner TA,et al. A conditional replication-competent adenoviral vector,Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis[J]. Cancer Res, 2001,61(16):6 012-6 019.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部